Add to a list

Suspension of trading

CARMAT Stock Börse Stuttgart

CXT

FR0010907956

Medical Equipment, Supplies & Distribution

OTC Markets Traded

Delayed Börse Stuttgart			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-

09-01	CARMAT SAS Publishes Results Of EFICAS Clinical Study On Aeson Total Artificial Heart As Bridge-To-Transplant Therapy	CI
01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris

Analysts' recommendations: CARMAT

09/05/25	Carmat: Invest Securities raises target price
11/04/25	Carmat: Invest Securities still a buyer, but cuts TP
04/02/25	Carmat: Invest Securities slightly lowers its target
09/01/25	Carmat: Invest Securities upgrades to buy
09/01/25	Carmat: Oddo BHF reduces its price target

More recommendations

News in other languages: CARMAT

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

More news

Managers and Directors: CARMAT

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	01/09/2016
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	12/12/2018
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	01/04/2025

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	02/01/2017
Michael Mack BRD	Director/Board Member	79	20/04/2017

More insiders

Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	6.15M 6.99M 5.79M 5.29M 9.89M 671M 9.97M 69.37M 26.93M 342M 26.25M 25.68M 1.11B	P/E 2023	-3.09x	P/E 2024	-0.95x
Enterprise Value	59.25M 67.41M 55.81M 51M 95.31M 6.47B 96.12M 669M 260M 3.3B 253M 248M 10.7B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

09-01	CARMAT SAS Publishes Results Of EFICAS Clinical Study On Aeson Total Artificial Heart As Bridge-To-Transplant Therapy	CI
01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-06	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-06	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-04	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
15/10/25	CAC 40 Surges on LVMH Results and Easing US-China Tensions
15/10/25	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
15/10/25	Carmat says liquidation review postponed until Nov 25	RE
01/10/25	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-04	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
29/10/25	CARMAT : Inside Information / Other news releases	PU
29/10/25	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
15/10/25	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-.--%	-.--%	-	-	7.08M
STRYKER CORPORATION	-1.34%	-5.27%	-27.78%	-5.44%	105B
SMITH & NEPHEW PLC	-0.30%	-3.60%	-25.48%	-3.27%	11.24B
GLAUKOS CORPORATION	+0.91%	-5.25%	+82.88%	+105.74%	9.05B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-1.29%	+3.85%	-48.74%	-66.54%	4.2B
DOUBLE MEDICAL TECHNOLOGY INC.	-0.91%	+6.88%	-21.15%	+29.07%	2.51B
INSPIRE MEDICAL SYSTEMS, INC.	-0.36%	-5.42%	-10.68%	-62.81%	2B
INSIGHT LIFETECH CO., LTD.	-3.28%	+6.48%	-	-	2.01B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-1.43%	+0.79%	-19.92%	-27.50%	1.55B
Average	-0.61%	-1.02%	-10.13%	-4.39%	17.18B
Weighted average by Cap.	+0.78%	-3.57%	-20.38%	-0.19%

	2023	2024
Net sales	3.84M 4.37M 3.61M 3.3M 6.17M 419M 6.22M 43.31M 16.81M 214M 16.39M 16.03M 693M	7.34M 8.36M 6.92M 6.32M 11.81M 802M 11.91M 82.89M 32.18M 409M 31.37M 30.68M 1.33B
Net income	-53.87M -61.29M -50.74M -46.37M -86.66M -5.88B -87.39M -608M -236M -3B -230M -225M -9.73B	-51.4M -58.47M -48.41M -44.24M -82.68M -5.61B -83.38M -580M -225M -2.86B -220M -215M -9.29B
Net Debt	49.64M 56.47M 46.76M 42.73M 79.85M 5.42B 80.52M 560M 217M 2.76B 212M 207M 8.97B	53.1M 60.41M 50.02M 45.71M 85.43M 5.8B 86.14M 599M 233M 2.96B 227M 222M 9.59B

CARMAT Stock Börse Stuttgart

Stocks

CXT

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation: CARMAT

Latest news: CARMAT

Analysts' recommendations: CARMAT

Press Releases: CARMAT

News in other languages: CARMAT

Managers and Directors: CARMAT

Medical Devices & Implants

Financials

Company Profile